Alnylam Pharmaceuticals, Inc.
ALNY
$218.82
$1.840.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.15% | 10.50% | -25.75% | 447.63% | -295.75% |
| Total Depreciation and Amortization | 2.55% | 0.35% | -2.15% | -1.01% | -3.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.77% | 304.25% | -86.11% | 63.57% | 57.87% |
| Change in Net Operating Assets | 90.50% | -307.00% | 64.26% | -882.52% | 111.94% |
| Cash from Operations | 363.41% | -56.89% | -49.69% | 150.46% | 207.89% |
| Capital Expenditure | -58.84% | 6.26% | -91.83% | 15.05% | -59.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8,764.30% | 73.27% | -102.70% | 503.85% | -203.54% |
| Cash from Investing | -1,322.98% | 31.28% | -107.42% | 454.44% | -224.27% |
| Total Debt Issued | -- | -- | -100.11% | -- | -- |
| Total Debt Repaid | -- | -- | 95.42% | -- | -- |
| Issuance of Common Stock | 155.08% | -68.45% | -46.36% | -4.29% | 64.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4.65% | -95.48% | 276.30% | -805.59% | -7.89% |
| Cash from Financing | 130.60% | -65.32% | 110.11% | -677.17% | 68.57% |
| Foreign Exchange rate Adjustments | 65.39% | -23.91% | -514.99% | -103.37% | 95.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.49% | -67.70% | -55.96% | 302.66% | 74.66% |